Peter Farrell Sells 2,000 Shares of ResMed (NYSE:RMD) Stock

ResMed Inc. (NYSE:RMD) Director Peter Farrell sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $248.83, for a total value of $497,660.00. Following the completion of the sale, the director directly owned 66,773 shares of the company’s stock, valued at approximately $16,615,125.59. The trade was a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

ResMed Stock Up 0.6%

RMD opened at $252.47 on Friday. The stock’s fifty day simple moving average is $248.44 and its 200 day simple moving average is $263.21. ResMed Inc. has a 1-year low of $199.92 and a 1-year high of $293.81. The stock has a market cap of $36.84 billion, a PE ratio of 25.84, a price-to-earnings-growth ratio of 1.70 and a beta of 0.88. The company has a current ratio of 2.89, a quick ratio of 2.13 and a debt-to-equity ratio of 0.07.

ResMed (NYSE:RMD) last released its quarterly earnings data on Friday, October 31st. The medical equipment provider reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. ResMed had a net margin of 27.35% and a return on equity of 25.45%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the previous year, the business posted $2.20 earnings per share. As a group, research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Thursday, November 13th were paid a $0.60 dividend. The ex-dividend date was Thursday, November 13th. This represents a $2.40 dividend on an annualized basis and a yield of 1.0%. ResMed’s dividend payout ratio is 24.56%.

Analyst Ratings Changes

Several research firms have recently commented on RMD. Morgan Stanley set a $305.00 target price on ResMed in a research report on Friday, October 31st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ResMed in a report on Monday, December 29th. Stifel Nicolaus lowered their price objective on ResMed from $270.00 to $260.00 and set a “hold” rating on the stock in a research report on Thursday, December 18th. Royal Bank Of Canada boosted their target price on shares of ResMed from $300.00 to $303.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Finally, Wells Fargo & Company started coverage on shares of ResMed in a research note on Monday, October 13th. They issued an “equal weight” rating and a $280.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $296.09.

ResMed News Summary

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Zacks Research raised multiple near‑term and multi‑year EPS forecasts for RMD (modest bumps to quarterly forecasts and lifts to FY2026–FY2028: FY2026 to $10.62, FY2027 to $11.20 and FY2028 to $12.80). Upgrades signal stronger expected revenue/margin momentum and are a clear catalyst for buying interest. Zacks Upgrades
• Positive Sentiment: Large institutional activity (e.g., Norges Bank new stake and other funds materially increasing positions) supports conviction from long‑term investors and can underpin further accumulation ahead of earnings. Institutional Ownership
• Neutral Sentiment: ResMed set its Q2 FY2026 earnings release for Jan. 29 (after the close) with a webcast — a near‑term event that can amplify moves depending on results and guidance. Earnings Date
• Neutral Sentiment: Consensus remains constructive (MarketBeat shows a “Moderate Buy” with an average target ~ $296). That positive analyst backdrop supports buying but leaves limited room if guidance disappoints. Analyst Consensus
• Negative Sentiment: Insider selling: CEO Michael J. Farrell sold ~4,991 shares (~$248.46 avg) and Director Peter C. Farrell sold 2,000 shares (~$248.83 avg) on Jan. 7. While both retain large stakes, disclosed sales can create short‑term nervousness and are being watched by investors. SEC filings: CEO Form 4 and Director Form 4

Institutional Trading of ResMed

Several large investors have recently modified their holdings of the stock. Advisors Asset Management Inc. lifted its position in ResMed by 26.1% during the first quarter. Advisors Asset Management Inc. now owns 1,449 shares of the medical equipment provider’s stock worth $324,000 after purchasing an additional 300 shares during the period. Integrated Wealth Concepts LLC raised its position in shares of ResMed by 17.8% in the 1st quarter. Integrated Wealth Concepts LLC now owns 5,778 shares of the medical equipment provider’s stock valued at $1,293,000 after buying an additional 871 shares in the last quarter. Jones Financial Companies Lllp raised its position in shares of ResMed by 52.6% in the 1st quarter. Jones Financial Companies Lllp now owns 2,882 shares of the medical equipment provider’s stock valued at $645,000 after buying an additional 994 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of ResMed by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 739,007 shares of the medical equipment provider’s stock worth $165,427,000 after acquiring an additional 58,155 shares during the period. Finally, Great Lakes Advisors LLC boosted its position in shares of ResMed by 5.0% during the 1st quarter. Great Lakes Advisors LLC now owns 1,668 shares of the medical equipment provider’s stock worth $373,000 after acquiring an additional 80 shares in the last quarter. 54.98% of the stock is owned by institutional investors and hedge funds.

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.